Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

Research output: Contribution to journalArticlepeer-review

Abstract

Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.

Original languageEnglish
Article number1189
Number of pages9
JournalBiomolecules
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 2021

Keywords

  • Human activin B
  • ME/CFS
  • Visual analogue scale

Field of Science

  • 3.1 Basic medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)'. Together they form a unique fingerprint.

Cite this